Prot #NU CU16B01: A randomized phase II trial of fulvestrant with or without Ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negat

Project: Research project

Project Details

Effective start/end date2/1/1612/31/23


  • Columbia University (Prot #NU CU16B01)
  • Novartis Pharmaceuticals Corporation (Prot #NU CU16B01)